Related Content
- AlertJanuary 26, 2023
CMS Issues First Request for Public Comments on the Medicare Drug Price Negotiation Program “Small Biotech” Exception – Due March 27, 2023
- Goodwin InsightsJanuary 25, 2023
In the Metaverse, Existing Healthcare Rules Apply
- Goodwin InsightsJanuary 20, 2023
Implications of Abortion Laws for Fertility Services
- AlertJanuary 18, 2023
USPTO Launches the Cancer Moonshot Expedited Examination Pilot Program
- AlertJanuary 4, 2023
New Appropriations Bill Reforms Antitrust Laws and Modifies HSR Fees
- Big Molecule WatchDecember 31, 2022
Year in Review: Top Biosimilars-Related Regulatory Developments of 2022
- Life Sciences PerspectivesDecember 29, 2022
Congress Expands Pathway for Drug & Device Manufacturers’ Pre-Approval Communication of Health Care Economic Information to Payors, Formularies, & Similar Entities
- AlertDecember 28, 2022
Congress Expands Pathway for Drug & Device Manufacturers’ Pre-Approval Communication of Health Care Economic Information to Payors, Formularies, & Similar Entities
- EventsJanuary 26, 2023
The Inflation Reduction Act & Medicare Pricing for Drugs and Biologics
- Press ReleaseJanuary 26, 2023
Grey Wolf Therapeutics Closes Oversubscribed $49 Million Series B Financing to Advance First-of-its-Kind Neoantigen Creation Approaches
- In the PressJanuary 26, 2023
UK Biotech Financing Report 2022 (UK BioIndustry Association)
- In the PressJanuary 25, 2023
Phila. Law Firm Leaders Find Opportunity, Not Threat, in Goodwin Arrival (Law.com)
- In the PressJanuary 25, 2023
Goodwin's Philly Co-Chairs On Splashy Hirings (Law360)
- In the PressJanuary 24, 2023
Top 5 FDA Considerations for Medtech-Enabled Data Platforms (MedCity News)
- Press ReleaseJanuary 23, 2023
Goodwin Scales Its Leading Global Life Sciences Platform, Healthcare Private Equity and White Collar Practices
- In the PressJanuary 23, 2023
Goodwin Officially Enters Philadelphia with 14 Partners Across 3 Practice Groups (Philadelphia Business Journal)